.jpg "E-Cadherin CD324 IHC human Colon Carcinoma (CDH1 1525)")
.jpg "E-Cadherin CD324 IHC human Skin (CDH1 1525)")
.jpg "E-Cadherin IHC human Colon Carcinoma (CDH1 1525)")
.jpg "E-Cadherin IHC FFPE placenta (CDH1 1525)")
.jpg "E-Cadherin IHC FFPE prostate carcinoma (CDH1 1525)")
PDF DatasheetHuman Anti-E-Cadherin / CD324 Antibody Product Attributes
E-Cadherin / CD324 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-CDH1 antibody staining is expected to be primarily localized to the cell junctions, golgi apparatus and plasma membrane. There is variability in either the signal strength or the localization of signal in plasma membrane from cell to cell.
Observed Antibody Staining Data By Tissue Type:
Variations in E-Cadherin / CD324 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in cells in the tubules in kidney, epidermal cells in the skin, exocrine glandular cells in the pancreas, glandular cells in the appendix, breast, colon, duodenum, endometrium, epididymis, fallopian tube, gallbladder, parathyroid gland, prostate, rectum, salivary gland, seminal vesicle, small intestine, stomach and thyroid gland, keratinocytes in skin, Langerhans in skin, melanocytes in skin, pneumocytes in lung, respiratory epithelial cells in the nasopharynx, squamous epithelial cells in the cervix, uterine, esophagus, oral mucosa, tonsil and vagina, trophoblastic cells in the placenta and urothelial cells in the urinary bladder. More moderate antibody staining intensity was present in cells in the tubules in kidney, epidermal cells in the skin, exocrine glandular cells in the pancreas, glandular cells in the appendix, breast, colon, duodenum, endometrium, epididymis, fallopian tube, gallbladder, parathyroid gland, prostate, rectum, salivary gland, seminal vesicle, small intestine, stomach and thyroid gland, keratinocytes in skin, Langerhans in skin, melanocytes in skin, pneumocytes in lung, respiratory epithelial cells in the nasopharynx, squamous epithelial cells in the cervix, uterine, esophagus, oral mucosa, tonsil and vagina, trophoblastic cells in the placenta and urothelial cells in the urinary bladder. Low, but measureable presence of E-Cadherin / CD324 could be seen inmacrophages in lung. We were unable to detect E-Cadherin / CD324 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of E-Cadherin / CD324 expression as measured by anti-E-Cadherin / CD324 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | +++ | ++ | +++ | +++ | +++ | – | ++ | ++ | ++ | – | ++ | +++ | +++ | +++ | – | ++ | +++ | ++ | +++ | +++ |
| CDH1 Variability | ++ | ++ | ++ | + | + | + | ++ | ++ | ++ | + | ++ | ++ | + | + | ++ | ++ | ++ | ++ | + | ++ |
| E-Cadherin / CD324 General Information | |
|---|---|
| Alternate Names | |
| Cadherin-1, CAM 120/80, Epithelial Cadherin, E-cadherin, CD324 | |
| Molecular Weight | |
| 120-80kDa (Mature) ;135kDa (Precursor) | |
| Chromosomal Location | |
| 16q22.1 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | CDH1 |
| Entrez Gene ID | 999 |
| Ensemble Gene ID | ENSG00000039068 |
| RefSeq Protein Accession(s) | XP_011521790, XP_011521791, NP_001304113, NP_004351, NP_001304115, NP_001304114 |
| RefSeq mRNA Accession(s) | XM_011523488, NM_001317184, XM_011523489, NM_001317186, NM_004360, NM_001317185 |
| RefSeq Genomic Accession(s) | NG_008021, NC_000016, NC_018927 |
| UniProt ID(s) | B3GN61, A0A0U2ZQU7, P12830, Q9UII7 |
| UniGene ID(s) | B3GN61, A0A0U2ZQU7, P12830, Q9UII7 |
| HGNC ID(s) | 1748 |
| Cosmic ID(s) | CDH1 |
| KEGG Gene ID(s) | hsa:999 |
| PharmGKB ID(s) | PA26282 |
| General Description of E-Cadherin / CD324. | |
| Recognizes a protein of 120-80kDa, identified as E-cadherin. Cadherins comprise a family of Ca2+-dependent adhesion molecules that function to mediate cell-cell binding critical to the maintenance of tissue structure and morphogenesis. The classical cadherins, E-, N- and P-cadherin, consist of large extracellular domains characterized by a series of five homologous NH2 terminal repeats. The relatively short intracellular domains interact with a variety of cytoplasmic proteins, such as ?-catenin, to regulate cadherin function. E-cadherin plays an important role in epithelial cell adhesion. A decreased expression of E-cadherin is associated with metastatic potential and poor prognosis in breast cancer, prostate and esophageal cancer. In combination with p120 Catenin, it is useful for the differentiation between ductal (E-cadherin +) and lobular (E-cadherin -) breast carcinomas. It may also help in diagnosis of mesothelioma. | |
-150x150.jpg)
-150x150.jpg)
There are no reviews yet.